Table 3. Multivariate analyses of overall survival after treatment in a phase I clinical trial (n = 242 patients).
| Factor | p | Hazard ratio | 95% confidence interval | |
|---|---|---|---|---|
| Lower | Upper | |||
| Age <60 years | 0.029 | 1.374 | 1.034 | 1.827 |
| White | 0.511 | 1.126 | 0.790 | 1.606 |
| Serous carcinoma | 0.109 | 1.324 | 0.939 | 1.866 |
| ECOG performance status ≥1 | 0.310 | 1.174 | 0.861 | 1.599 |
| Normal lactate dehydrogenase levels | 0.047 | 1.342 | 1.004 | 1.795 |
| Albumin ≥3.5 g/dL (normal) | <0.001 | 3.060 | 1.987 | 4.712 |
| ≤2 metastatic sites | <0.001 | 1.637 | 1.229 | 2.179 |
| Prior antiangiogenic therapy | 0.015 | 0.704 | 0.530 | 0.935 |
| <3 prior lines of systemic therapy | 0.644 | 1.091 | 0.755 | 1.576 |